• Host-pathogen interactions
• Unnatural immunity and development of innovative vaccines target multidrug resistant organisms
• Novel antibody-based therapy
• Mechanisms of microbial sepsis and development of novel immunotherapies
• Antifungal drug discovery
• Rapid diagnostics

• Bsc, Kuwait University, Kuwait
• PhD, Loughborough University of Technology, UK
• Postdoctoral fellowship, Harbor-UCLA Medical Center

Maji A, Soutar CP, Zhang J, Lewandowska A, Uno BE, Yan S, Shelke Y, Murhade G, Nimerovsky E, Borcik CG, Arango AS, Lange JD, Marin-Toledo JP, Lyu Y, Bailey KL, Roady PJ, Holler JT, Khandelwal A, SantaMaria AM, Sanchez H, Juvvadi PR, Johns G, Hageman MJ, Krise J, Gebremariam T, Youssef EG, Bartizal K, Marr KA, Steinbach WJ, Ibrahim AS, Patterson TF, Wiederhold NP, Andes DR, Pogorelov TV, Schwieters CD, Fan TM, Rienstra CM, Burke MD. Tuning sterol extraction kinetics yields a renal-sparing polyene antifungal. Nature. 2023; PMCID: PMC10883201.

Soliman SSM, Baldin C, Gu Y, Singh S, Gebremariam T, Swidergall M, Alqarihi A, Youssef EG, Alkhazraji S, Pikoulas A, Perske C, Venkataramani V, Rich A, Bruno VM, Dunning Hotopp J, Mantis NJ, Edwards, Jr JE, Filler SG, Chamilos G, Vitetta ES, Ibrahim AS. Mucoricin is a Ricin-Like Toxin that is Critical for the Pathogenesis of Mucormycosis. Nature Microbiology. 2021: PMC7914224.

Ost KS, O’ Meara TR, Stephens WZ, Chiaro T, Zhou H, Penman J, Bell R, Catanzaro JR, Song D, Singh S, Call DH, Hwang-Wong E, Hanson KE, Valentine JF, Christensen KA, O’ Connell RM, Cormack B, Ibrahim AS, Palm NW, Noble S, Round JL. Adaptive immunity induces mutualism between commensal eukaryotes. Nature 2021; PMID: 34262174; NIHMSID:NIHMS1729888.

Singh S, Uppuluri P, Alqarihi A, Elhassan H, French S, Lockhart SR, Chiller T, Edwards, Jr JE, Ibrahim AS. The NDV-3A vaccine protects mice from multidrug resistant Candida auris infection. PLoS Pathogens 2019; PMCID: PMC6695204.

Gebremariam T, Alkhazraji S, Soliman SSM, Gu Y, Jeon HH, Zhang L, French SW, Stevens DA, Edwards Jr JE, Filler SG, Uppuluri P, Ibrahim AS.  Anti-cotH3 antibodies protect mice from mucormycosis by prevention of invasion and augmenting opsonophagocytosis. Science Advances 2019; PMCID:PMC6561750.

A list of publications can be found at Google Scholar and NIH Bibliography

• ICAAC Program Committee Award in the area of Therapy and Prevention of Microbial Disease 2011
• The Lundquist Institute Richard B. Weitzman Memorial Award for Meritorious Research in
• Basic/Translational Science  2017
• Elected fellow of the European Confederation of Medical Mycology (ECMM) 2018
• Elected fellow of the American Academy of Microbiology (AAM)         2019
• Standing member of the NIAID Drug Discovery and Mechanisms of Antimicrobial Resistance (DDR) and Drug Discovery and Molecular Pharmacology A (DMPA) Study sections 2019-2023
• The Medical Mycology Society of the Americas Billy H. Cooper Award for continuous outstanding achievement in clinical mycology. 2024

• Cross-Kingdom Vaccine Targeting Healthcare-Associated Priority Pathogens
• Novel toxins and receptors in mucormycosis pathogenesis and treatment
• Humanized monoclonal antibodies to treat mucormycosis
• Multiplex rapid immunoassay for invasive fungal disease
• Development of antifungal drugs in collaboration with industry partners (Basilea, Elion Therapeutics, and Scynexis,)